ArticleFrontiers in oncology2023

ctDNA-based detection of molecular residual disease in stage I-III non-small cell lung cancer patients treated with definitive radiotherapy.

Emily S Lebow et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.